35158-39-5

Basic information

• Product Name: 3-BROMO-4-(4-CHLORO-PHENYL)-4-OXO-BUTYRIC ACID
• Synonyms: BENZOBROM;3-BROMO-4-(4-CHLOROPHENYL)-4-OXOBUTANOIC ACID;3-BROMO-4-(4-CHLORO-PHENYL)-4-OXO-BUTYRIC ACID;3-BROMO-[3-(4-CHLOROBENZOYL)PROPIONIC ACID];3-BROMO-(4-CHLOROBENZOYL)-PROPIONICACID;β-Bromo-4-chloro-γ-oxobenzenebutyric acid;Benzenebutanoic acid, b-broMo-4-chloro-g-oxo-
• CAS NO: 35158-39-5
• Molecular Formula: C₁₀H₈BrClO₃
• Molecular Weight: 291.53
• EINECS: 252-408-5
• Product Categories: Aromatic Propionic Acids
• Mol File: 35158-39-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 417.4°Cat760mmHg
• Flash Point: 206.2°C
• Appearance: /
• Density: 1.674g/cm³
• Vapor Pressure: 1.03E-07mmHg at 25°C
• CAS DataBase Reference: 3-BROMO-4-(4-CHLORO-PHENYL)-4-OXO-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-(4-CHLORO-PHENYL)-4-OXO-BUTYRIC ACID(35158-39-5)
• EPA Substance Registry System: 3-BROMO-4-(4-CHLORO-PHENYL)-4-OXO-BUTYRIC ACID(35158-39-5)

Safety Data

• Hazardous Substances Data: 35158-39-5(Hazardous Substances Data)

Usage

General Description

3-Bromo-4-(4-chloro-phenyl)-4-oxo-butyric acid is a chemical compound that belongs to the class of organic compounds known as alpha-keto acids and derivatives. It is a derivative of butyric acid and is characterized by the presence of a bromine atom, a chloro-substituted phenyl group, and a ketonic functional group. 3-BROMO-4-(4-CHLORO-PHENYL)-4-OXO-BUTYRIC ACID is often used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds due to its versatile reactivity and the ability to introduce functional groups to the synthesized molecules. Additionally, it may also possess biological activity and be employed in research and development in the pharmaceutical industry.

InChI:InChI=1/C10H8BrClO3/c11-8(5-9(13)14)10(15)6-1-3-7(12)4-2-6/h1-4,8H,5H2,(H,13,14)/p-1/t8-/m0/s1

Upstream product

• 3984-34-7 4-(4-chlorophenyl)-4-oxobutanoic acid 

Downstream Products

• 53515-14-3 [4-(4-chloro-phenyl)-2-pyridin-2-yl-thiazol-5-yl]-acetic acid 
• 53514-98-0 [4-(4-chloro-phenyl)-2-p-tolyl-thiazol-5-yl]-acetic acid 
• 53515-01-8 2-p-methoxyphenyl-4-p-chlorophenylthiazol-5-ylacetic acid 
• 53514-96-8 [4-(4-chloro-phenyl)-2-o-tolyl-thiazol-5-yl]-acetic acid 
• 53514-97-9 [4-(4-chloro-phenyl)-2-m-tolyl-thiazol-5-yl]-acetic acid 
• 53515-00-7 [2-(4-bromo-phenyl)-4-(4-chloro-phenyl)-thiazol-5-yl]-acetic acid 
• 53515-03-0 4-[5-carboxymethyl-4-(4-chloro-phenyl)-thiazol-2-yl]-benzoic acid 
• 75887-11-5 [3-(4-chloro-phenyl)-3-hydroxy-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazol-2-yl]-acetic acid 
• 18046-21-4 fentiazac 
• 23822-14-2 [2,4-bis-(4-chloro-phenyl)-thiazol-5-yl]-acetic acid 
• 39225-26-8 3-(p-Chlorophenyl)-2,3-dihydro-3-hydroxy-thiazolo[3,2-a]-benzimidazole-2-acetic acid 
• 54013-01-3 3-(6-chloro-1,1-dioxo-1,2(4)-dihydro-1λ⁶-benzo[1,2,4]thiadiazin-3-ylsulfanyl)-4-(4-chloro-phenyl)-4-oxo-butyric acid 
• 53515-02-9 [4-(4-chloro-phenyl)-2-(4-dimethylamino-phenyl)-thiazol-5-yl]-acetic acid 
• 60717-53-5 4-(p-Chlorphenyl)-4-oxo-3-hydroxy-butancarbonsaeure 

Relevant articles and documents

INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE

Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.

AMINO-SUBSTITUTED AZO-HETEROCYCLIC COMPOUNDS FOR TREATING INFLAMMATORY CONDITIONS

Compounds of formula (I) are CRTH2 antagonists, useful in the treatment of inflammatory, autoimmune, respiratory or allergy disease: wherein X1 is -S-, -O-, -N=N-. -NR5-, -CR5=CR6-, -CR5=N-, wherein R5 and R6 are independently hydrogen or C1-C3 alkyl; R1 is hydrogen or C1-C3 alkyl or cyclopropyl; R2 is an optionally substituted phenyl or 5- or 6-membered monocyclic heteroaryl ring; R3 is an optionally substituted carbocyclic ring of 3 to 7 ring atoms, or an optionally substituted 4-, 5- or 6-membered monocyclic heterocyclic ring; R4 is a group other than hydrogen, methyl or ethyl of formula Q-[Alk1]m-[X]n-[Alk2]p-[Z}s- wherein m, n p, and s are independently 0 or 1 ; Q is hydrogen or an optionally substituted 4-, 5- or 6-membered monocyclic heterocyclic ring; Alk1 and Alk2 are independently optionally substituted C1-C3 alkylene radicals; X is -O-, -S-, -C(=O)-, - S(=O)-, -S(=O)2-, -CH(R7)-, -N(R7)-, or, in either orientation -SO2N(R7)- or - C(=O)N(R7)-, wherein R7 is hydrogen, or R7 represents a C2-C4 bridge between the C or N atom of X to which it is attached and a carbon atom of Alk2 and Z is -CH2, - C(=O) or -S(=O)2.

4-aryl oxazoles

Novel oxazole derivatives of the formula STR1 (wherein R1 is hydrogen or a straight, branched or cyclic alkyl group of 1 to 6 carbon atoms, R2 is hydrogen, halogen, trifluoromethyl, or a straight, branched or cyclic alkylthio of 1 to 3 carbon atoms, and n is 1 or 2) or pharmaceutically acceptable salts or esters thereof are synthesized through several routes. The derivatives have hypoglycemic, glucose tolerance improving and insulin sensitivity increasing activities and are of value as antidiabetic drugs.